Directorio
We are doing this study to see if the combination of an experimental drug called BGB-3245 (the study drug) and panitumumab is a safe and effective option for patients who have colorectal or pancreatic cancer with an RAS mutation.
We are doing this study to find out if an investigational drug called bemcentinib (the study drug) is a safe and effective option when it is combined with the standard therapy for non-small cell lung cancer (1 immunotherapy drug and 2 chemotherapy drugs).
We are doing this study to collect data, liquid biopsies (blood and urine), and cancer specimens from women with primary epithelial ovarian, peritoneal, or tubal cancer. We are using this information and these samples to create a biobank that might identify future therapeutic targets and help develop new therapies for these types of cancer.
We are doing this study to get a better understanding of how several different factors influence our overall health. The factors we will study include:
- Trauma
- Social determinants of health (nonmedical factors that can influence health)
- Allostatic load (wear and tear on the body)
- Biological response to trauma
We are doing this study to find out if an experimental drug called BNT142 (the study drug) is a safe and effective treatment for select cancers with solid tumors that test positive for a protein called Claudin 6 (CLDN6).
Collection of samples will allow for increased and more focused research on skin conditions and perhaps eventually lead to the development of improved treatment outcomes.
We are doing this study to find the most safe and effective dose of an experimental drug called BMS-986460 (the study drug) for men with metastatic castration resistant prostate cancer.
We are doing this study to see if a pair of experimental drugs called botensilimab and balstilimab are safe and effective options for colorectal cancer.